* Cara Therapeutics Inc is expected to show a fall in quarterly revenue when it reports results on November 11 (estimated) for the period ending September 30 2024
* The Stamford Connecticut-based company is expected to report a 66.8% decrease in revenue to $1.616 million from $4.87 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Cara Therapeutics Inc is for a loss of 25 cents per share.
* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Cara Therapeutics Inc is $1.00, above its last closing price of $0.35.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.27 -0.27 -0.37 Missed -35
Mar. 31 2024 -0.40 -0.40 -0.56 Missed -40.7
Dec. 31 2023 -0.44 -0.41 -0.59 Missed -43.2
Sep. 30 2023 -0.53 -0.52 -0.52 Met 0
Jun. -0.53 -0.54 -0.58 Missed -7.7
30 2023
Mar. 31 2023 -0.51 -0.52 -0.49 Beat 6
Dec. 31 2022 -0.35 -0.56 -75
Sep. 30 2022 -0.43 -0.42 -0.43 Missed -2.7
This summary was machine generated November 8 at 15:51 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments